The investments are part of Lilly's ongoing commitment to expand production, especially for its top-selling diabetes and obesity drugs, Mounjaro and Zepbound, respectively. The company has committed ...

Eli Lilly & Co. closed $71.28 below its 52-week high ($972.53), which the company achieved on August 22nd.

We recently compiled a list of the 10 Best ESG Stocks To Buy Now. In this article, we are going to take a look at where Eli ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 589.06% and ...

Sept 5 (Reuters) - U.S. drugmaker Eli Lilly (LLY.N), opens new tab has signed a research deal with privately held AI-focused firm Genetic Leap to develop genetic medicines, the latter said on Thursday ...

Eli Lilly has entered into a research deal with artificial intelligence-focused firm Genetic Leap for up to $409 million to develop genetic medicines, the latter said on Thursday. (Reporting by Mariam ...

As we proceed with the earnings season, here are earnings from several major US companies you may have missed. The post 3 US ...

We recently published a list of 10 Stocks That May Be Splitting Soon. In this article, we are going to take a look at where ...

Indianapolis-based Eli Lilly and Co. is ramping up its campaign against imitations of its blockbuster appetite-suppressing drugs, seeking to put an end to a regulatory designation that has allowed ...

International drugmaker, Eli Lilly, announced plans in May to invest $5.3 billion (€4.9 billion) in a new manufacturing site ...

The surge in interest investors have displayed for companies delivering weight loss drugs has been impressive. Indeed, the ...

Eli Lilly And Co. (NYSE:LLY ... In July, it agreed to acquire Morphic, which develops oral therapies for chronic diseases. At the same time, management announced that Zepbound’s new doses ...